News

Evidence Mounts for Early Treatment of Smoldering Myeloma

Publish date: January 3, 2012

 

FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY

Dr. Mateos reported receiving honoraria from Celgene, Millennium Pharmaceuticals, and Janssen. A coauthor reported receiving honoraria from Celgene and Janssen, and four coauthors reported employment with Celgene, the maker of lenalidomide. Dr. Beksac reported receiving honoraria from and serving as a speaker for Celgene and Janssen-Cilag.

Pages

Recommended Reading

Combining MRI With Prostate Ultrasound Biopsy Bests Biopsy Alone
MDedge Hematology and Oncology
Factors Predict Contralateral Breast Cancer Risk in BRCA Carriers
MDedge Hematology and Oncology
Breast Cancer Linked to Benign Thyroid Disease
MDedge Hematology and Oncology
Meta-Analysis: Pregnancy-Associated Breast Cancer Fares Poorly
MDedge Hematology and Oncology
Recent Diabetes Increases Breast Cancer Risk
MDedge Hematology and Oncology
Acupuncture Flops as Relief for Muscle Pain From Aromatase Inhibitors
MDedge Hematology and Oncology
Vitamin D Deficiency/Breast Cancer Link Questioned
MDedge Hematology and Oncology
Return ED Visits by Sickle Cell Patients Common
MDedge Hematology and Oncology
Bevacizumab Effective With First-Line Treatment for Ovarian Cancer
MDedge Hematology and Oncology
'Best Results' Yet for Poor-Prognosis Elderly With DLBCL
MDedge Hematology and Oncology

Related Articles